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Guidelines to Reduce Cardiovascular Risk
The goals of the American College of Cardiology (ACC)
and the American Heart Association (AHA) are to prevent
cardiovascular diseases (CVD); improve the management
of people who have these diseases through professional
education and research; and develop guidelines, standards,
and policies that promote optimal patient care and car-
diovascular health. Toward these objectives, the ACC and
AHA have collaborated with the National Heart, Lung,
and Blood Institute (NHLBI) and stakeholder and pro-
fessional organizations to develop clinical practice guide-
lines for assessment of cardiovascular risk, lifestyle
modiﬁcations to reduce cardiovascular risk, management of
blood cholesterol in adults, and management of overweight
and obesity in adults.
In 2008, the NHLBI initiated these guidelines by
sponsoring rigorous systematic evidence reviews for
each topic by expert panels convened to develop critical
questions (CQs), interpret the evidence, and craft rec-
ommendations. In response to the 2011 report from the
Institute of Medicine on the development of trustworthy
clinical guidelines (1), the NHLBI Advisory Council
recommended that the NHLBI focus speciﬁcally on
reviewing the highest-quality evidence and partner with
other organizations to develop recommendations (2,3).
Accordingly, in June 2013 the NHLBI initiated collabo-
ration with the ACC and AHA to work with other or-
ganizations to complete and publish the 4 guidelines
noted above and make them available to the widest
possible constituency. Recognizing that the Expert Work
Group/Work Groups did not consider evidence beyond
2011 (except as speciﬁed in the methodology), the ACC,
AHA, and collaborating societies plan to begin updating
these guidelines starting in 2014.
The joint ACC/AHA Task Force on Practice Guide-
lines (Task Force) appointed a subcommittee to shepherd
this transition, communicate the rationale and expecta-
tions to the writing panels and partnering organizations,
and expeditiously publish the documents. The ACC/
AHA and partner organizations recruited a limited
number of expert reviewers for ﬁduciary examination of
content, recognizing that each document had undergone
extensive peer review by representatives of the NHLBI
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2937Advisory Council, key federal agencies, and scientiﬁc ex-
perts. Each writing panel responded to comments from
these reviewers. Clariﬁcations were incorporated where
appropriate, but there were no substantive changes because
the bulk of the content was undisputed.
Although the Task Force led the ﬁnal development of
these prevention guidelines, they differ from other ACC/
AHA guidelines. First, as opposed to an extensive com-
pendium of clinical information, these documents are
signiﬁcantly more limited in scope and focus on selected
CQs on each topic, based on the highest-quality evidence
available. Recommendations were derived from random-
ized trials, meta-analyses, and observational studies eval-
uated for quality and were not formulated when sufﬁcient
evidence was not available. Second, the text accompanying
each recommendation is succinct, summarizing the evi-
dence for each question. The Full Panel/Work Group
Reports include more detailed information about the ev-
idence statements that serve as the basis for recommen-
dations. Third, the format of the recommendations differs
from other ACC/AHA guidelines. Each recommendation
has been mapped from the NHLBI grading format to the
ACC/AHA Classiﬁcation of Recommendation/Level of
Evidence (COR/LOE) construct (Table 1) and is
expressed in both formats. Because of the inherent dif-
ferences in grading systems and the clinical questions
driving the recommendations, alignment between the
NHLBI and ACC/AHA formats is in some cases
imperfect. Explanations of these variations are noted in
the recommendation tables, where applicable.
In consultation with NHLBI, the policies adopted by
the writing panels to manage relationships of authors with
industry and other entities (RWI) are outlined in the
methods section of each panel report. These policies were
in effect when this effort began in 2008 and throughout
the writing process and voting on recommendations, until
the process was transferred to ACC/AHA in 2013. In the
interest of transparency, the ACC/AHA requested that
panel authors resubmit RWI disclosures as of July 2013.
Relationships relevant to this guideline are disclosed in
Appendix 1. None of the ACC/AHA expert reviewers had
relevant RWI (Appendix 2). See Appendix 3 for a list of
abbreviations used in the guideline.
Systematic evidence reports and accompanying sum-
mary tables were developed by the expert panels and
NHLBI. The guideline was reviewed by the ACC/
AHA Task Force and approved by the ACC Board of
Trustees, and the AHA Science Advisory and Co-
ordinating Committee. In addition, ACC/AHA sought
endorsement from other stakeholders, including profes-
sional organizations. It is the hope of the writing panels,
stakeholders, professional organizations, NHLBI, and
Task Force that the guidelines will garner the widest
possible readership for the beneﬁt of patients, providers,
and the public health.These guidelines are meant to deﬁne practices that
meet the needs of patients in most circumstances and
are not a replacement for clinical judgment. The ulti-
mate decision about care of a particular patient must be
made by the healthcare provider and patient in light of
the circumstances presented by that patient. As a result,
situations might arise in which deviations from these
guidelines may be appropriate. These considerations
notwithstanding, in caring for most patients, clinicians
can employ the recommendations conﬁdently to reduce
the risks of atherosclerotic cardiovascular disease
(ASCVD) events.
See Tables 2 and 3 for an explanation of the NHLBI
recommendation grading methodology.
1. Introduction
1.1. Organization of the Work Group
The Risk Assessment Work Group (Work Group) was
composed of 11 members and 5 ex-ofﬁcio members,
including internists, cardiologists, endocrinologists, and
experts in cardiovascular epidemiology, biostatistics,
healthcare management and economics, and guideline
development.
1.2. Document Review and Approval
A formal peer review process, which included 12 expert
reviewers and representatives of federal agencies, was
initially completed under the auspices of the NHLBI.
This document was also reviewed by 3 expert reviewers
nominated by the ACC and the AHA when the man-
agement of the guideline transitioned to the ACC/AHA.
The ACC and AHA Reviewers’ RWI information is
published in this document (Appendix 2).
This document was approved for publication by the
governing bodies of the ACC and AHA and endorsed by
the American Association of Cardiovascular and Pulmo-
nary Rehabilitation, American Society for Preventive
Cardiology, American Society of Hypertension, Associa-
tion of Black Cardiologists, National Lipid Association,
Preventive Cardiovascular Nurses Association, and
WomenHeart: The National Coalition for Women With
Heart Disease.
1.3. Charge to the Work Group
The Work Group was 1 of 3 work groups appointed by the
NHLBI to develop its own recommendations and provide
cross-cutting input to 3 Panels for updating guidelines on
blood cholesterol, blood pressure (BP), and overweight/
obesity. The Work Group was asked to examine the sci-
entiﬁc evidence on risk assessment for initial ASCVD
events and to develop an approach for quantitative risk
assessment that could be used in practice and used or
adapted by the risk factor panels (blood cholesterol,
Table 1. Applying Classiﬁcation of Recommendation and Level of Evidence
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials.
Even when randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.
*Data available from clinical trials or registries about the usefulness/efﬁcacy in different subpopulations, such as sex, age, history of diabetes, history of prior myocardial infarction, history of heart
failure, and prior aspirin use.
yFor comparative-effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments
or strategies being evaluated.
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2938hypertension, and obesity) in their guidelines and algo-
rithms. Speciﬁcally, the Work Group was charged with 2
tasks:
1. To develop or recommend an approach to quantitative
risk assessment that could be used to guide care; and
2. To use systematic review methodology to pose and
address a small number of questions judged to be
critical to reﬁning and adopting risk assessment in
clinical practice.1.4. Methodology and Evidence Review
This guideline is based on the Full Work Group Report
supplement, which is provided as a supplement to theguideline. The Full Work Group Report supplement
contains background and additional material related to
content, methodology, evidence synthesis, rationale, and
references and is supported by the NHLBI Systematic
Evidence Review, which can be found at (http://www.
nhlbi.nih.gov/guidelines/cvd_adult/risk_assessment/). These
documents also describe the process for the development
of novel, comprehensive multivariable risk equations for
the prediction of 10-year risk of development of ASCVD
in non-Hispanic African-American and non-Hispanic
white men and women from 40 to 79 years of age. These
equations were developed from several long-standing pop-
ulation-based cohort studies funded by the NHLBI. Ten-
year risk was deﬁned as the risk of developing a ﬁrst
ASCVD event, deﬁned as nonfatal myocardial infarction or
Table 3. NHLBI Quality Rating of the Strength of Evidence
Type of Evidence Quality Rating*
 Well-designed, well-executedy RCT that adequately
represent populations to which the results are applied
and directly assess effects on health outcomes.
 Meta-analyses of such studies.
Highly certain about the estimate of effect. Further
research is unlikely to change our conﬁdence in the
estimate of effect.
High
 RCT with minor limitationsz affecting conﬁdence
in, or applicability of, the results.
 Well-designed, well-executed nonrandomized
controlled studiesx and well-designed, well-executed
observational studiesk.
 Meta-analyses of such studies.
Moderately certain about the estimate of effect. Further
research may have an impact on our conﬁdence in
the estimate of effect and may change the estimate.
Moderate
 RCT with major limitations.
 Nonrandomized controlled studies and observational
studies with major limitations affecting conﬁdence
in, or applicability of, the results.
 Uncontrolledclinical observationswithout anappropriate
comparison group (e.g., case series, case reports).
 Physiological studies in humans.
 Meta-analyses of such studies.
Low certainty about the estimate of effect. Further
research is likely to have an impact on our conﬁdence
in the estimate of effect and is likely to change the
estimate.
Low
*In some cases, other evidence, such as large all-or-none case series (e.g., jumping from
airplanes or tall structures), can represent high- or moderate-quality evidence. In such cases,
the rationale for the evidence rating exception should be explained by the Work Group and
clearly justiﬁed.
y“Well-designed, well-executed” refers to studies that directly address the question; use
adequate randomization, blinding, and allocation concealment; are adequately powered; use
intention-to-treat analyses; and have high follow-up rates.
zLimitations include concerns with the design and execution of a study that result in
decreased conﬁdence in the true estimate of the effect. Examples of such limitations include
but are not limited to: inadequate randomization, lack of blinding of study participants or
outcome assessors, inadequate power, outcomes of interest that are not prespeciﬁed for the
primary outcomes, low follow-up rates, and ﬁndings based on subgroup analyses. Whether the
limitations are considered minor or major is based on the number and severity of ﬂaws in
design or execution. Rules for determining whether the limitations are considered minor or
major and how they will affect rating of the individual studies will be developed collaboratively
with the methodology team.
xNonrandomized controlled studies refer to intervention studies where assignment to inter-
vention and comparison groups is not random (e.g., quasi-experimental study design).
kObservational studies include prospective and retrospective cohort, case-control, and cross-
sectional studies.
NHLBI indicates National Heart, Lung, and Blood Institute; and RCT, randomized controlled
trials.
Table 2. NHLBI Grading of the Strength of
Recommendations
Grade Strength of Recommendation*
A Strong recommendation
There is high certainty based on evidence that the net beneﬁty
is substantial.
B Moderate recommendation
There is moderate certainty based on evidence that the net beneﬁt is
moderate to substantial, or there is high certainty that the net
beneﬁt is moderate.
C Weak recommendation
There is at least moderate certainty based on evidence that there is a
small net beneﬁt.
D Recommendation against
There is at least moderate certainty based on evidence that there is
no net beneﬁt or that risks/harms outweigh beneﬁts.
E Expert opinion (“There is insufﬁcient evidence or evidence is
unclear or conﬂicting, but this is what the Work Group
recommends.”)
Net beneﬁt is unclear. Balance of beneﬁts and harms cannot be
determined because of no evidence, insufﬁcient evidence,
unclear evidence, or conﬂicting evidence, but the Work Group
thought it was important to provide clinical guidance and
make a recommendation. Further research is recommended in
this area.
N No recommendation for or against (“There is insufﬁcient evidence or
evidence is unclear or conﬂicting.”)
Net beneﬁt is unclear. Balance of beneﬁts and harms cannot be
determined because of no evidence, insufﬁcient evidence, unclear
evidence, or conﬂicting evidence, and the Work Group thought
no recommendation should be made. Further research is
recommended in this area.
*In most cases, the strength of the recommendation should be closely aligned with the quality
of the evidence; however, under some circumstances, there may be valid reasons for making
recommendations that are not closely aligned with the quality of the evidence (e.g., strong
recommendation when the evidence quality is moderate, such as smoking cessation to reduce
cardiovascular disease risk or ordering an ECG as part of the initial diagnostic work-up for a
patient presenting with possible MI). Those situations should be limited and the rationale
explained clearly by the Work Group.
yNet beneﬁt is deﬁned as beneﬁts minus risks/harms of the service/intervention.
ECG indicates electrocardiogram; MI, myocardial infarction; and NHLBI, National Heart, Lung,
and Blood Institute.
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2939coronary heart disease (CHD) death or fatal or nonfatal
stroke, over a 10-year period among people free from
ASCVD at the beginning of the period.
In addition, through evaluation of evidence developed by
systematic reviews of the literature, the Work Group
addressed the following 2 CQs:
CQ1. “What is the evidence with regard to reclas-
siﬁcation or contribution to risk assessment when
high-sensitivity C-reactive protein (hs-CRP), apoli-
poprotein B (ApoB), glomerular ﬁltration rate,
microalbuminuria, family history, cardiorespiratory
ﬁtness, ankle-brachial index (ABI), carotid intima-
media thickness (CIMT), or coronary artery cal-
cium (CAC) score is considered in addition to the
variables that are in the traditional risk scores?”
CQ2. “Are models constructed to assess the long-
term (‡15 years or lifetime) risk of a ﬁrst cardiovas-
cular disease (CVD) event in adults effective inassessing variation in long-term risk among adults at
low and/or intermediate short-term risk, whether
analyzed separately or in combination?”
The evidence and recommendations in the guideline
focus on the large proportion of the adult populationwithout
clinical signs or symptoms of ASCVDwhomerit evaluation
for the primary prevention of ASCVD. They do not apply to
those with clinically manifest ASCVD, who require sec-
ondary prevention approaches, or to highly-selected patient
subgroups, such as those with symptoms suggestive ofCVD,
who require diagnostic strategies rather than risk assessment.
Furthermore, these recommendations were not developed
Table 4. Summary of Recommendations for Risk Assessment
Recommendations NHLBI Grade
NHLBI Evidence
Statements ACC/AHA COR ACC/AHA LOE
Assessment of 10-Year Risk of a First Hard ASCVD Event
1. The race- and sex-speciﬁc Pooled Cohort Equations* to predict 10-year
risk of a ﬁrst hard ASCVD event should be used in non-Hispanic African
Americans and non-Hispanic whites, 40–79 years of age.
B (Moderate) N/A I B
(4–8)
2. Use of the sex-speciﬁc Pooled Cohort Equations for non-Hispanic whites
may be considered for estimation of risk in patients from populations
other than African Americans and non-Hispanic whites.
E (Expert Opinion) N/A IIb C
CQ1: Use of Newer Risk Markers After Quantitative Risk Assessment
1. If, after quantitative risk assessment, a risk-based treatment decision is
uncertain, assessment of 1 of the followingdfamily history, hs-CRP,
CAC score, or ABIdmay be considered to inform treatment decision
making.
E (Expert Opinion) Appendix 4 IIby B
(9–17)
2. Routine measurement of CIMT is not recommended in clinical practice
for risk assessment for a ﬁrst ASCVD event.
N (No recommendation
for or against)
Appendix 4 III: No Beneﬁty B
(12,16,18)
3. The contribution of ApoB, CKD, albuminuria, and cardiorespiratory ﬁtness
to risk assessment for a ﬁrst ASCVD event is uncertain at present.
N (No recommendation
for or against)
Appendix 4 d d
CQ2: Long-Term Risk Assessment
1. It is reasonable to assess traditional ASCVD risk factorsz every 4–6 years
in adults 20–79 years of age who are free from ASCVD and to estimate
10-year ASCVD risk every 4–6 years in adults 40–79 years of age who are
free from ASCVD.
B (Moderate) Appendix 5
CQ2/ES7
IIa B
(19,20)
2. Assessment of 30-year or lifetime ASCVD risk on the basis of traditional
risk factorsz may be considered in adults 20–59 years of age who are
free from ASCVD and are not at high short-term risk.
C (Weak) Appendix 5
CQ2/ES2,
CQ2/ES3,
CQ2/ES4,
CQ2/ES5,
CQ2/ES6
IIb C
(20–22)
A downloadable spreadsheet enabling estimation of 10-year and lifetime risk of ASCVD and a Web-based calculator is available at http://my.americanheart.org/cvriskcalculator and http://www.
cardiosource.org/en/Science-And-Quality/Practice-Guidelines-and-Quality-Standards/2013-Prevention-Guideline-Tools.aspx.
*Derived from the ARIC (Atherosclerosis Risk in Communities) study (8), Cardiovascular Health Study (5), CARDIA (Coronary Artery Risk Development in Young Adults) study (7), and Framingham original
and offspring cohorts (4,6).
yBased on new evidence reviewed during ACC/AHA update of evidence.
zAge, sex, total cholesterol, high-density lipoprotein cholesterol, systolic BP, use of antihypertensive therapy, diabetes, and current smoking.
ABI indicates ankle-brachial index; ACC, American College of Cardiology; AHA, American Heart Association; ApoB, apolipoprotein B; ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure;
CAC, coronary artery calcium; CIMT, carotid intima-media thickness; CKD, chronic kidney disease; COR, Class of Recommendation; CQ, critical question, ES, evidence statement; hs-CRP, high-sensitivity
C-reactive protein; LOE, Level of Evidence; NHLBI, National Heart, Lung, and Blood Institute; and d, not applicable.
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2940for use in speciﬁc subgroups of asymptomatic individuals at
unusually high risk, such as those with genetically deter-
mined extreme values of traditional risk factors (e.g., patients
with familial hypercholesterolemia).
2. Risk Assessment: Recommendations
See Table 4 for a summary of the recommendations for
risk assessment.
3. Approach to Risk Assessment
In addressing its charge, the Work Group recognized
the need for a risk assessment approach that was based on
the types of data that primary care providers could easily
collect and that could be implemented in routine clinical
practice. After deliberation, the Work Group endorsed the
existing and widely used paradigm of matching the in-
tensity of preventive efforts with the individual’s absolute
risk (23,24). The Work Group acknowledges that none
of the risk assessment tools or novel risk markersexamined in the present document have been formally
evaluated in randomized controlled trials of screening
strategies with clinical events as outcomes. Nevertheless, this
approach balances an understanding of an individual’s ab-
solute risk of CVD and potential treatment beneﬁts against
the potential absolute risks for harm from therapy. With the
use of this framework, treatment can be targeted to those
most likely to beneﬁt without undue risk of harm, in the
context of a “risk discussion.” A risk discussion could include
the assessment of the patient’s risk of ASCVD, as well as
potential beneﬁts, negative aspects, risks, and patient pref-
erences with regard to initiation of relevant preventive
therapies.
By its nature, such an approach requires a platform for
reliable quantitative estimation of absolute risk based on
data from representative population samples. It is
important to note that risk estimation is based on group
averages, which are then applied to individual patients in
practice. This process is admittedly imperfect; no one has
10% or 20% of a heart attack during a 10-year period.
Individuals with the same estimated risk will either have
or not have the event of interest, and only those patients
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2941who are destined to have an event can have their event
prevented by therapy. The criticism of the risk-
estimation approach to treatment decision making also
applies to the alternative, and much less efﬁcient
approach, of checking the patient’s characteristics against
numerous and complex inclusion and exclusion criteria
for a potentially large number of pertinent trials. Only a
small fraction of trial participants have events, and only a
fraction of these events are prevented by therapy. Using
either approach, the clinician must apply the average
results obtained from groups of patients to the individual
patient in practice.
Given the modiﬁcation and adoption of the Framing-
ham 10-year risk score for CHD risk assessment by the
Third Report of the National Cholesterol Education
Program Expert Work Group on Diagnosis, Evaluation,
and Treatment of High Blood Cholesterol in Adults
(Adult Treatment Panel III) (24) and the uptake of this
algorithm by practice sites across the United States, the
Work Group began by discussing the value of retaining
this algorithm. In collaboration with other NHLBI panels,
the Work Group decided not to use this algorithm in its
2013 recommendations because of the algorithm’s deriva-
tion in an exclusively white sample population and the
limited scope of the outcome (in determining CHD
alone). Rather, the Work Group derived risk equations
from community-based cohorts that are broadly represen-
tative of the U.S. population of whites and African
Americans, and the Work Group focused on estimation of
ﬁrst hard ASCVD events (deﬁned as ﬁrst occurrence of
nonfatal myocardial infarction, CHD death, or fatal or
nonfatal stroke) as the outcome of interest because they
were deemed to be of greater relevance to both patients and
providers. The focus on hard ASCVD, rather than CHD
alone, is also consistent with evidence reviewed in a
statement from the AHA and American Stroke Associa-
tion calling for the inclusion of ischemic stroke in the
outcome of interest for CVD risk assessment (25).
Numerous multivariable risk scores and equations
have been derived and published (Appendix 6; for more
details, see the Full Work Group Report supplement). As
part of its deliberations, the Work Group considered pre-
viously published risk scores with validation in NHLBI
cohort data as one possible approach. However, several
persistent concerns with existing risk equations were
identiﬁed, including nonrepresentative or historically
dated populations, limited ethnic diversity, narrowly
deﬁned endpoints, endpoints inﬂuenced by provider pref-
erences (e.g., elective revascularizations), and endpoints
with poor reliability (e.g., angina and heart failure). Given
the inherent limitations of existing scores, theWorkGroup
judged that a new risk score was needed to address some of
the deﬁciencies of existing scoresdfor example, the need
for a population sample that approaches, to the degree
possible, the ideal sample for algorithm development and
closely represents the U.S. population.Data are sparse on the use and impact of absolute risk
scores in clinical practice in primary-prevention settings
(26). Two systematic reviews, based on few studies, sup-
port the conclusion that risk assessment, combined with
counseling, is associated with favorable but modest
changes in patient knowledge and intention to change and
in provider prescribing behavior and risk factor control
(27,28). No data are available on hard event outcomes.
The Work Group speciﬁcally calls for research in this area
(Section 8).
The Work Group notes that the 2009 ACCF/AHA
Performance Measures for the Primary Prevention of
Cardiovascular Disease in Adults speciﬁcally recom-
mended use of global CVD risk estimation in clinical
practice (29). Likewise, the U.S. Preventive Services
Task Force recommendations for aspirin (30), the NHLBI
Adult Treatment Panel III recommendations (24), and
European (31) and Canadian (32,33) guidelines for pri-
mary prevention of CVD, among others, have all recom-
mended the use of absolute risk assessment for decision
making about the intensity of lifestyle and pharmacological
preventive interventions. Risk scores have been imple-
mented in practice through paper scoring sheets and,
increasingly, through Web sites and downloadable appli-
cations. The electronic medical record can be adapted to
estimate absolute risks automatically by using patient data
and published equations, and it is anticipated that risk
estimation with this technology will become a mainstream
application of the current and future risk algorithms.4. Development of New Pooled Cohort
ASCVD Risk Equations
Having made the decision to develop new equations to
estimate the 10-year risk of developing a ﬁrst ASCVD
event, the Work Group used the best available data from
community-based cohorts of adults, with adjudicated
endpoints for CHD death, nonfatal myocardial infarction,
and fatal or nonfatal stroke. Cohorts that included African-
American or white participants with at least 12 years of
follow-up were included. Data from other racial/ethnic
groups were insufﬁcient, precluding their inclusion in the
ﬁnal analyses. The ﬁnal pooled cohorts included partici-
pants from several large, racially and geographically diverse,
modern NHLBI-sponsored cohort studies, including the
ARIC (Atherosclerosis Risk in Communities) study (8),
the Cardiovascular Health Study (5), and the CARDIA
(Coronary Artery Risk Development in Young Adults)
study (7), combined with applicable data from the Fra-
mingham Original and Offspring Study cohorts (4,6).
The Work Group used state-of-the-art statistical
methods to derive and internally validate the Pooled Cohort
Equations, which provide sex- and race-speciﬁc estimates
of the 10-year risk of ASCVD for African-American and
white men and women 40 to 79 years of age. The variables
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equations are age, total cholesterol, high-density lipopro-
tein cholesterol, systolic BP (including treated or untreated
status), diabetes mellitus (diabetes), and current smoking
status.
An expanded description of the derivation and valida-
tion of the Pooled Cohort Equations, as well as the means
for implementing them in clinical practice, is provided in
Appendix 7. Additional details are provided in the Full
Work Group Report supplement. A speciﬁc clinical
vignette is also provided as an example in Appendix 7. In
the clinical vignette, the 10-year risk is calculated for a
patient 55 years of age who is a nonsmoker without dia-
betes, and with total cholesterol level of 213 mg/dL, high-
density lipoprotein cholesterol level of 50 mg/dL, and
untreated systolic BP of 120 mm Hg. With these values
used in the Pooled Cohort Equations, the predicted 10-
year ASCVD risks are 2.1% for white women, 3.0% for
African-American women, 5.3% for white men, and 6.1%
for African-American men.
Numerous other potential risk markers were consid-
ered for inclusion in the Pooled Cohort Equations:
for many, no additional utility was demonstrated when
they were included; for others, data are insufﬁcient at
the present time to determine their additional value.
The equations were also assessed in external validation
studies with data from other available cohorts. Other
than the Framingham CHD risk score (and its derivative
ATP III risk assessment proﬁle) and the European
SCORE (System for Cardiac Operative Risk Evalua-
tion) algorithm for CVD death, these equations have
been subjected to more rigorous validation than other
currently available equations, and they are the only risk
assessment equations that include signiﬁcant numbers of
African Americans and that focus on estimation of
10-year risk of the clinically relevant endpoint of ASCVD.
The Work Group speciﬁcally calls for further research to
develop similar equations applicable to other ethnic
groups, to validate the utility of the Pooled Cohort
Equations in diverse primary-prevention settings, and to
assess the potential beneﬁt of novel risk markers when
added to these equations, so that the equations maybe
modiﬁed or expanded over time as new data become
available.
4.1. Recommendations for Assessment of
10-Year Risk of a First Hard ASCVD Event
Recommendation 1. The race- and sex-speciﬁc Pooled
Cohort Equations* to predict 10-year risk of a ﬁrst hard
ASCVD event should be used in non-Hispanic African
Americans and non-Hispanic whites, 40 to 79 years of age.*Ten-year risk was deﬁned as the risk of developing a ﬁrst ASCVD event, deﬁned
as nonfatal myocardial infarction, CHD death, or fatal or nonfatal stroke, over a
10-year period among people free from ASCVD at the beginning of the period.NHLBI Grade: B (Moderate); ACC/AHA COR: I; LOE: B
Recommendation 2. Use of the sex-speciﬁc Pooled
Cohort Equations for non-Hispanic whites may be
considered for estimation of risk in patients from pop-
ulations other than African Americans and non-Hispanic
whites.
NHLBI Grade: E (Expert Opinion); ACC/AHA COR: IIb;
LOE: C
A web-based application enabling estimation of 10-year
and lifetime risk of ASCVD is available at http://my.
americanheart.org/cvriskcalculator and http://www.cardio
source.org/en/Science-And-Quality/Practice-Guidelines-
and-Quality-Standards/2013-Prevention-Guideline-Tools.
aspx.5. Implications for Risk Assessment
A range of estimated 10-year risk of a ﬁrst hard
ASCVD event is illustrated in the Full Work Group
Report supplement (Tables 8 through 11), across a
broad range of risk factor burdens for selected combi-
nations of the risk factors in sex–race groups (African-
American and white women and men). The estimated
risks are speciﬁc to deﬁned combinations of the risk
factors and demonstrate how they vary over a broad
spectrum of potential proﬁles. Risk factor levels that are
more adverse than those shown in these tables should
always be associated with a higher estimated risk. For
example, if a given risk factor combination indicates
an estimated 10-year risk of hard ASCVD of 8%, but a
patient has a higher level of systolic BP or total
cholesterol, or a lower level of high-density lipoprotein
cholesterol, than shown for that table cell, then the
estimated risk would be 8%. Because the estimated
probabilities can become unstable when approaching
the limits of the sample data, the risk probabilities are
truncated at 1% and 30%. The proportions of the U.S.
adult population, 40 to 79 years of age, in selected
strata of estimated 10-year risk of hard ASCVD events,
are shown overall and by sex and race/ethnicity in
Table 5. When compared with non-Hispanic whites,
estimated 10-year risk of ASCVD is generally lower in
Hispanic-American and Asian-American populations
and higher in American-Indian populations (34,35);
hence, the lack of race/ethnicity-speciﬁc risk algorithms
is an important gap in our efforts to understand and
prevent ASCVD in these populations. Although the
development of algorithms speciﬁc to these racial/
ethnic groups is encouraged, in the interim, providers
may consider using the equations for non-Hispanic
whites for these patients. When doing so, the esti-
mated risks may be overestimates, especially for His-
panic and Asian Americans.
Table 5. Distribution of Estimated 10-Year Risk of a First Hard ASCVD Event in the CVD-Free, Nonpregnant U.S. Population,
40 to 79 Years of Age, by Sex and Race/Ethnicity*
Predicted 10-Year Risk of Hard ASCVD Event
<2.5% 2.5%–4.9% 5.0%–7.4% 7.5%–9.9% 10.0%–14.9% 15.0%–19.9% 20.0%
Total
% (95% CI) 33.4 (31.2–35.5) 21.0 (19.4–22.7) 12.7 (11.4–14.0) 7.4 (6.5–8.3) 8.9 (8.1–9.6) 6.3 (5.6–7.1) 10.2 (9.5–11.0)
n 33,534,000 21,151,000 12,766,000 7,470,000 8,940,000 6,380,000 10,300,000
Sex
Men
% (95% CI) 17.4 (15.2–19.7) 22.7 (20.3–25.1) 15.6 (13.8–17.4) 10.1 (8.5–11.6) 12.1 (10.7–13.5) 8.8 (7.4–10.2) 13.3 (12.1–14.4)
n 8,386,000 10,950,000 7,511,000 4,847,000 5,849,000 4,248,000 6,388,000
Women
% (95% CI) 48.0 (44.8–51.3) 19.5 (17.3–21.6) 10.0 (8.3–11.8) 5.0 (3.8–6.2) 5.9 (5.1–6.7) 4.1 (3.4–4.7) 7.5 (6.5–8.4)
n 25,148,000 10,200,000 5,256,000 2,622,000 3,091,000 2,131,000 3,912,000
Race/Ethnicity
White
Men
% (95% CI) 18.0 (15.0–21.1) 22.4 (19.4–25.3) 15.7 (13.3–18.1) 10.0 (8.2–11.8) 11.7 (9.9–13.5) 8.7 (7.0–10.4) 13.6 (12.3–14.9)
n 6,467,000 8,016,000 5,616,000 3,584,000 4,189,000 3,112,000 4,870,000
Women
% (95% CI) 47.1 (43.0–51.1) 20.4 (17.7–23.0) 10.7 (8.6–12.8) 5.1 (3.6–6.7) 5.5 (4.6–6.5) 4.1 (3.4–4.9) 7.1 (5.9–8.2)
n 18,175,000 7,863,000 4,136,000 1,984,000 2,132,000 1,596,000 2,725,000
African American
Men
% (95% CI) 1.4 (0.3–2.6) 23.9 (19.9–28.0) 20.6 (17.0–24.2) 11.8 (8.8–14.8) 17.4 (14.3–20.5) 11.1 (8.2–13.9) 13.8 (11.0–16.7)
n 60,000 1,008,000 866,000 495,000 731,000 466,000 583,000
Women
% (95% CI) 36.5 (32.4–40.6) 18.7 (15.6–21.8) 10.9 (8.6–13.2) 6.5 (5.0–7.9) 9.4 (7.2–11.7) 5.7 (4.2–7.2) 12.3 (9.5–15.0)
n 1,921,000 985,000 572,000 339,000 496,000 300,000 645,000
Hispanic
Men
% (95% CI) 24.0 (19.8–28.1) 22.1 (17.9–26.2) 13.2 (10.8–15.6) 10.6 (8.1–13.0) 11.4 (9.9–12.9) 6.2 (4.6–7.9) 12.6 (9.4–15.7)
n 1,303,000 1,200,000 718,000 574,000 619,000 339,000 683,000
Women
% (95% CI) 59.4 (54.3–64.4) 14.5 (11.5–17.5) 7.5 (5.4–9.6) 4.5 (2.6–6.4) 4.9 (3.4–6.5) 3.0 (2.0–3.9) 6.3 (4.7–7.9)
n 3,293,000 803,000 418,000 248,000 273,000 164,000 347,000
Others
Men
% (95% CI) 20.8 (10.8–30.7) 27.1 (18.0–36.3) 11.6 (4.9–18.2) 7.2 (0.6–13.8) 11.5 (4.5–18.6) 12.3 (5.9–18.8) 9.4 (3.0–15.8)
n 555,000 726,000 310,000 193,000 309,000 330,000 251,000
Women
% (95% CI) 59.8 (50.2–69.3) 18.6 (10.8–26.5) 4.4 (0–8.7) 1.7 (0–3.5) 6.4 (2.1–10.7) 2.4 (0.4–4.5) 6.7 (2.3–11.0)
n 1,757,000 548,000 128,000 49,000 188,000 71,000 195,000
*Data derived by applying the Pooled Cohort Equations to the National Health and Nutrition Examinations Surveys, 2007–2010 (N¼5,367, weighted to 100,542,000 U.S. population).
ASCVD indicates atherosclerotic cardiovascular disease; and CVD, cardiovascular disease.
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6.1. Critical Question 1
“What is the evidence with regard to reclassiﬁcation
or contribution to risk assessment when hs-CRP,
ApoB, glomerular ﬁltration rate, microalbuminuria,
family history, cardiorespiratory ﬁtness, ABI, CAC,
or CIMT is considered in addition to the variables
that are in the traditional risk scores?”The concept of matching the intensity of risk factor
management to the estimated risk of CVD has been well
established since the 27th Bethesda Conference in 1996
(23). As a consequence, widespread attention has focused
on the accuracy and reliability of risk assessment. Claims
that a minority of the risk of CVD can be explained by the
major traditional risk factors or that most patients pre-
senting with CHD have no elevated traditional risk factors
have been disproved (36,37). Nonetheless, the desire to
improve existing quantitative risk-estimation tools has
Table 6. Expert Opinion Thresholds for Use of Optional
Screening Tests When Risk-Based Decisions About
Initiation of Pharmacological Therapy Are Uncertain
After Quantitative Risk Assessment
Measure
Support Revising
Risk Assessment
Upward
Do Not Support
Revising Risk
Assessment
Family history
of premature
CVD
Male <55 years of age
Female <65 years of age
(ﬁrst-degree relative)
Occurrences at older
ages only (if any)
hs-CRP 2 mg/L <2 mg/L
CAC score 300 Agatston units
or 75th percentile
for age, sex, and
ethnicity*
<300 Agatston units
and <75th percentile
for age, sex, and
ethnicity*
ABI <0.9 0.9
*For additional information, see http://www.mesa-nhlbi.org/CACReference.aspx.
ABI indicates ankle-brachial index; CAC, coronary artery calcium; CVD, cardiovascular
disease; and hs-CRP, high-sensitivity C-reactive protein.
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new risk markers for CVD that might further enhance risk
assessment.
CQ1 was developed to address whether newer risk
markers have been identiﬁed that actually improve risk
assessment enough to warrant routine measurement in
clinical practice. This question applies to risk assessment in
the general populationdthat is, the typical asymptomatic
adult in routine clinical practice. This question does not
address other highly selected patient subgroups, such as
those with symptoms suggestive of CVD.
CQ1 was addressed through 2 independent ap-
proaches. First, in the process of developing the Pooled
Cohort Equations, the additional risk markers listed in
CQ1 were tested for inclusion in the model if they were
available in the databases and could be evaluated on the
basis of at least 10 years of follow-up. A review of meta-
analyses and systematic reviews published before
September 19, 2013, was conducted in 2 stages. In the
ﬁrst stage, meta-analyses and systematic reviews pub-
lished before April 2011 were identiﬁed and reviewed. In
a second stage, conducted to update the evidence base
before publication, additional meta-analyses and system-
atic reviews published before September 19, 2013, were
identiﬁed and reviewed against the same criteria applied
in the ﬁrst stage. The reliance on published meta-analyses
to evaluate novel biomarkers is a conservative approach
that helps avoid the inﬂuence of positive publication bias
that can occur early in the evaluation of a novel associ-
ation and assures that we relied on a mature body of
evidence (38).
Members of the Work Group proposed an initial list of
novel risk markers for inclusion in CQ1, which was then
prioritized during several rounds of discussion. In select-
ing the ﬁnal list, the Work Group gave priority to factors
that have engendered substantial discussion in the scien-
tiﬁc community and that could be reasonably considered
as potentially feasible for widespread population use by
primary care providers in routine clinical settings in the
United States. In these deliberations, the Work Group
considered availability, cost, assay reliability, and risks of
the test or downstream testing. The ﬁnal list of new risk
markers to be evaluated included several blood and urine
biomarkers (hs-CRP, ApoB, creatinine [or estimated
glomerular ﬁltration rate], and microalbuminuria), several
measures of subclinical cardiovascular disease (CAC,
CIMT, and ABI), family history, and cardiorespiratory
ﬁtness. Other novel potential screening tools maybe the
subject of future guideline updates. Guidance published
by Hlatky et al (39) was considered during discussion of
the utility of incorporating these new risk factors into
routine risk assessment. Special attention was given to
the additional value these markers contributed to risk
assessment in terms of discrimination, calibration, re-
classiﬁcation, and cost-effectiveness, in the context of any
potential harm.6.1.1. Summary of Systematic Reviews and
Meta-Analyses for CQ1
Thirteen systematic review articles or meta-analyses met
the inclusion/exclusion criteria (9–18,40–42). Publication
dates ranged from 2008 to 2013. The Work Group
reviewed the 13 systematic reviews and meta-analyses and
created a table to list their key ﬁndings (Appendix 4).
None of these markers has been evaluated as a screening
test in randomized controlled trials with clinical events as
outcomes. On the basis of current (limited) evidence, it is
the opinion of the Work Group that among the novel risk
markers, assessments of family history of premature CVD,
as well as measurement of hs-CRP, CAC, and ABI, show
some promise for clinical utility. Table 6 provides expert
opinion on thresholds of these measures that may be
considered for clinical decision making.
The Work Group notes that the review by Peters et al.
(16) provides evidence to support the contention that
measuring CAC is likely to be the most useful of the
current approaches to improving risk assessment among
individuals found to be at intermediate risk after formal
risk assessment. Furthermore, the Work Group recog-
nizes that the “2010 ACCF/AHA Guideline for
Assessment of Cardiovascular Risk in Asymptomatic
Adults” made recommendations for CAC testing (43).
However, the Work Group notes that the outcomes in
the studies reviewed by Peters et al. (16) and by
Greenland et al. (43) were CHD outcomes, not hard
ASCVD events that included stroke; hence, uncertainty
remains about the contribution of CAC assessment to
estimation of 10-year risk of ﬁrst hard ASCVD events
after formal risk assessment with the new Pooled Cohort
Equations. Furthermore, issues of cost and radiation
exposure related to measuring CAC were discussed,
resulting in some uncertainty about potential risks of
more widespread screening, which resulted in a decision
in the present guideline to make assessment of CAC an
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dividuals for whom a risk-based treatment decision is
uncertain after formal risk estimation. The Work Group
notes that this ACC/AHA COR IIb recommendation is
consistent with the recommendations in the 2010
ACCF/AHA guideline (43) for patients with a 10-year
CHD risk of <10%, as well as for many other patients,
because of the lower risk threshold (7.5% 10-year risk of a
ﬁrst hard ASCVD event) adopted by the “2013 ACC/
AHA Guideline on the Treatment of Blood Cholesterol
to Reduce Atherosclerotic Cardiovascular Risk in Adults”
(44) for recommending initiation of statin therapy for
ASCVD risk reduction.
Furthermore, it was noted that measurement of ApoB,
albuminuria, glomerular ﬁltration rate, or cardiorespiratory
ﬁtness is of uncertain value. Finally, the Work Group
judged that the evidence provided by Den Ruijter et al.
(18), reviewed during the ACC/AHA update period, in
combination with the concerns about measurement quality,
provided sufﬁcient rationale to recommend against
measuring CIMT in routine clinical practice for risk
assessment for a ﬁrst ASCVD event. If any of the 9
markers considered in the present report is assessed in
selected patients, the use of the information to guide
treatment decisions will require sound clinician judgment
and should be based on shared decision making.
6.1.2. Recommendations for CQ1: Use of Newer
Risk Markers After Quantitative Risk Assessment
Recommendation 1. If, after quantitative risk assessment,
a risk-based treatment decision is uncertain, assessment of
1 or more of the followingdfamily history, hs-CRP, CAC
score, or ABIdmay be considered to inform treatment
decision making.
NHLBI Grade: E (Expert Opinion); ACC/AHA COR:
IIby, LOE: By
Recommendation 2. Routine measurement of CIMT is
not recommended in clinical practice for risk assessment
for a ﬁrst ASCVD event.
NHLBI Grade: N (No recommendation for or against);
ACC/AHA COR III: No Beneﬁty, LOE: B
Recommendation 3. The contribution of ApoB, chronic
kidney disease, albuminuria, and cardiorespiratory ﬁtness
to risk assessment for a ﬁrst ASCVD event is uncertain at
present.
NHLBI Grade: N (No recommendation for or against)
6.2. Critical Question 2
“Are models constructed to assess the long-term
(‡15 years or lifetime) risk of a ﬁrst CVD event in
adults effective in assessing variation in long-termyBased on new evidence reviewed during ACC/AHA update of the evidence.risk among adults at low or intermediate short-
term risk, whether analyzed separately or in
combination?”
Younger men (typically <50 years of age) and most women
have low (e.g., <5% or <10%) predicted 10-year risks
of CHD and more broad CVD outcomes, even in the
presence of signiﬁcant risk factor burden (45,46). How-
ever, extensive epidemiological, pathological, and basic
science data indicate that the development of atheroscle-
rosis, the precursor of ASCVD, occurs over decades and is
related to long-term and cumulative exposure to causal,
modiﬁable risk factors. Thus, a life-course perspective on
risk assessment and prevention must be taken, especially
among younger individuals. The primary value of risk
factor measurement and quantitative long-term risk esti-
mation in younger adults is 2-fold: ﬁrst, to identify risk
in individuals with extreme values of risk factors (e.g.,
familial hypercholesterolemia); and second, to provide
risk information and context for the potential beneﬁts
of lifestyle modiﬁcation. When posing CQ2, the Work
Group did not anticipate that long-term or lifetime
risk would replace 10-year risk assessment as the founda-
tion for absolute risk assessment and clinical decision
making. Rather, longer-term risk estimates, if found to be
useful, could provide adjunctive information for risk
communication.
CQ2 was developed to assess the utility of long-term
and lifetime risk assessment as an adjunct to short-term
(10-year) risk assessment. It was recognized that there is
little “disconnect” with regard to approaches to prevention
when the 10-year risk estimate is high (e.g., >10% pre-
dicted 10-year risk); such patients merit intensive preven-
tion efforts and should be considered for drug therapy
to reduce or modify adverse levels of causal risk factors.
CQ2 was selected for evaluation to determine whether
quantitative or semiquantitative long-term risk assessment
would provide differential information that could be
useful in risk communication, speciﬁcally to patients esti-
mated to be at lower short-term risk. However, it is unclear
what the long-term predicted and observed risks for CHD
and CVD are among individuals who are at low predicted
10-year risk. CQ2 was designed to identify studies that
assessed both short- and long-term risk, focusing in
particular on those studies that provide long-term out-
comes data for groups predicted to be at low 10-year risk.
If a sufﬁciently large proportion of the population is at high
long-term risk despite being at low short-term risk, then
incorporating long-term risk assessment into routine
clinical practice might have value for informing risk dis-
cussions with patients and guiding therapeutic lifestyle
counseling and other aspects of care.
6.2.1. Summary of Evidence for CQ2
Ten studies that met inclusion/exclusion criteria were
identiﬁed by the systematic review performed in April
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ranged from 1999 to 2009. All of the studies were obser-
vational. On the basis of these studies, 7 evidence state-
ments were adopted (Appendix 5).
Multiple sources provided consistent evidence for the
associations of traditional risk factors with events occurring
during both short-term and long-term follow-up. The
important associations are best represented and understood
in the context of multivariable risk equations that reliably
predict absolute risk of ASCVD events. In addition, most
of these risk factors are both causal and modiﬁable,
which indicates their central clinical importance for
ASCVD prevention efforts. Given the additional evidence
suggesting improved risk prediction with updated clinical
covariates, the Work Group makes the following
recommendations.
6.2.2. Recommendations for CQ2:
Long-Term Risk Assessment
Recommendation 1. It is reasonable to assess traditional
ASCVD risk factors* every 4 to 6 years in adults 20 to 79
years of age who are free from ASCVD and to estimate
10-year ASCVD risk every 4 to 6 years in adults 40 to 79
years of age who are free from ASCVD.
NHLBI Grade: B (Moderate); ACC/AHA COR: IIa, LOE: B
Recommendation 2. Assessment of 30-year or lifetime
ASCVD risk on the basis of traditional risk factors* may be
considered in adults 20 to 59 years of age who are free from
ASCVD and are not at high short-term risk.
NHLBI Grade: C (Weak); ACC/AHA COR: IIb, LOE: C
A web-based application enabling estimation of 10-year
and lifetime risk of ASCVD is available at http://my.
americanheart.org/cvriskcalculator and http://www.
cardiosource.org/en/Science-And-Quality/Practice-Guide
lines-and-Quality-Standards/2013-Prevention-Guideline-
Tools.aspx.
Evidence was not found on the utility of lifetime
risk assessment for guiding pharmacological therapy de-
cisions, and the Work Group judged that long-term
and lifetime risk information may be used more appro-
priately at this time to motivate therapeutic lifestyle change
in younger individuals. This perspective inﬂuenced the
choice of age 20 years as the starting point for long-term
risk assessment, despite a threshold of age 40 years for
short-term 10-year ASCVD risk assessment.
Long-term and lifetime risk estimation may be less
valuable for individuals who are found to be at high short-
term (10-year) risk according to multivariable equations,
for whom decisions about prevention efforts may be clear.
However, an understanding of long-term risk may provide*Age, sex, total cholesterol, high-density lipoprotein cholesterol, systolic BP, use of
antihypertensive therapy, diabetes, and current smoking.a means of encouraging adherence to lifestyle or pharma-
cological therapies, especially for patients who might have
difﬁculty understanding the importance of their short-term
risk. Likewise, for older individuals or those with limited
life expectancy, clinical considerations should dictate the
intensity of risk assessment and prevention efforts.7. Implementation Considerations for
Risk Assessment
A suggested approach for incorporating these recommen-
dations into clinical practice is shown in Figure 1. For
patients 20 to 79 years of age who are free from clinical
ASCVD, the ﬁrst step is to assess ASCVD risk factors.
Although it is reasonable to assess ASCVD risk factors in
individuals younger or older than this age range, limita-
tions of available data prevented the development of robust
risk assessment algorithms in those populations. Hence, for
patients outside this age range, providers should refer to
applicable clinical practice guidelines (i.e., pediatric (53)
and adult primary prevention guidelines (44,54,56). Risk
assessment should be repeated every 4 to 6 years in persons
who are found to be at low 10-year risk (<7.5%). Begin-
ning at age 40 years, formal estimation of the absolute
10-year risk of ASCVD is recommended (20,21). Long-
term or lifetime risk estimation is recommended for all
persons who are between 20 and 39 years of age and for
those between 40 and 59 years of age who are determined
to be at low 10-year risk (<7.5%). As shown in Figure 1,
all patients should receive applicable risk information and
appropriate lifestyle counseling. The 10-year risk estimates
provided by the new Pooled Cohort Equations differ from
those generated by the Adult Treatment Panel III algo-
rithm in several respects (24), as discussed in detail in the
Full Work Group Report supplement. To summarize, on
the basis of the risk estimation algorithm recommended
by Adult Treatment Panel III, approximately 31.9% of
the ASCVD-free, nonpregnant U.S. population between
40 and 79 years of age have a 10-year risk of a ﬁrst hard
CHD event of at least 10% or have diabetes. On the basis
of the new Pooled Cohort Equations described here,
approximately 32.9% have a 10-year risk of a ﬁrst hard
ASCVD of at least 7.5%. The outcomes and thresholds of
these 2 approaches are different, but the overlap of these
2 means of deﬁning high-risk groups is substantial, at
roughly 75%. Nonetheless, these important differences
make simple linear conversions imprecise. We recommend
that healthcare organizations convert to these new Pooled
Cohort Equations as soon as practical (Appendix 7). A
web-based application enabling estimation of 10-year
and lifetime risk of ASCVD is available at http://
my.americanheart.org/cvriskcalculator and http://www.
cardiosource.org/en/Science-And-Quality/Practice-Guidelines-
and-Quality-Standards/2013-Prevention-Guideline-Tools.
aspx.
Figure 1. Implementation of Risk Assessment Work Group Recommendations
ACC indicates American College of Cardiology; AHA, American Heart Association; ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; and NHLBI, National Heart,
Lung, and Blood Institute.
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29478. Evidence Gaps and
Future Research Needs
The Work Group strongly recommends continued
research to ﬁll gaps in knowledge about short- and long-
term ASCVD risk assessment and outcomes in all racial/
ethnic groups, across the age spectrum, and in women and
men. Future research should include analyses of short- and
long-term risk in diverse groups, optimal communication
of ASCVD risk information, utility of short-and long-
term risk assessment for motivating behavioral change and
adherence to therapy, utility of short-and long-term risk
assessment for inﬂuencing risk factor levels and clinical
outcomes, utility of differential information conveyed by
short- and long-term risk assessment, and utility of novel
risk markers in short- and long-term risk assessment.
9. Conclusions
The Work Group’s approach to risk assessment represents
a step forward in ASCVD prevention that is large enough
to justify the challenges inherent in implementing a new
approach, rather than staying with the CHD risk assess-
ment approach recommended previously. The ﬁnal rec-
ommendations are summarized in Table 4 and Figure 1.
Two major advantages of this approach are the ability to
estimate risk for a broader-based ASCVD outcome thatis more relevant to additional segments of the popula-
tion, including women and African Americans, and the
ability to provide risk estimates speciﬁc to African
Americans. Promotion of lifetime risk estimation may
represent an additional step forward in supporting lifestyle
behavior change counseling efforts. Periodic updates of
the guidelines should address numerous issues related to
risk assessment.
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2953Appendix 4. Evidence Statements for CQ1Evidence
Statement
Number Author/Group Factor Evidence Statement/Conclusion
1 USPSTF (9) hs-CRP “Strong evidence indicates that CRP is associated with CHD events. Moderate, consistent evidence suggests that adding
CRP to risk prediction models among initially intermediate-risk persons improves risk stratiﬁcation.”
“Few studies directly assessed the effect of CRP on risk reclassiﬁcation in intermediate-risk persons.”
hs-CRP was associated with risk, and its use resulted in some reclassiﬁcation in intermediate-risk persons, but it was not
clear whether this reclassiﬁcation led to a net improvement in prediction. Values of receiver operating curve C-statistics
(measures of discrimination) are mentioned but not reported; hence, no evidence on discrimination, calibration, net
reclassiﬁcation index, or cost-effectiveness was provided.
Reports some impact on reclassiﬁcation, probably modest (pp. 488–491).
2 Helfand
et al., 2009 (12)
hs-CRP, CAC,
CIMT, ABI
With regard to risk assessment for major CHD, the authors concluded that, “The current evidence does not support the
routine use of any of the 9 risk factors for further risk stratiﬁcation of intermediate-risk persons.” The 9 risk factors
examined were: hs-CRP, CAC score as measured by electron-beam computed tomography, lipoprotein (a) level,
homocysteine level, leukocyte count, fasting blood glucose, periodontal disease, ABI, and CIMT.
hs-CRP was associated with CHD and led to some reclassiﬁcation. The authors cite the JUPITER results to support the
conclusion that hs-CRP testing may be useful in intermediate-risk patients to drive statin therapy. The Work Group
recognizes that more recent individual study results have been published. Updated systematic reviews addressing
discrimination, calibration, reclassiﬁcation, and cost issues in the context of the newer ASCVD risk assessment model
proposed in the present document are needed.
CAC was associated with CHD and with some reclassiﬁcation, but the size and value of this reclassiﬁcation are
uncertain. The document provides little evidence with regard to discrimination, calibration, and cost-effectiveness. The
Work Group also is concerned about radiation and incidental ﬁndings. The Work Group recognizes that more recent
individual study results have been published. Updated systematic reviews addressing discrimination, calibration,
reclassiﬁcation, cost, and safety issues in the context of the newer ASCVD risk assessment model proposed in the
present document are needed.
CIMT was associated with CHD, but the document provides little evidence for reclassiﬁcation, discrimination, calibration,
and cost-effectiveness. The Work Group also has concerns about measurement issues. Standardization of CIMT
measurement is a major challenge. The Work Group recognizes that more recent individual study results have been
published. Updated systematic reviews addressing discrimination, calibration, reclassiﬁcation, cost, and measurement
(standardization) issues in the context of the newer ASCVD risk assessment model proposed in this document are
needed.
ABI was associated with CHD and some reclassiﬁcation, but the size and value of this reclassiﬁcation are uncertain.
Evidence suggests some improvement in discrimination, but the document provides little evidence with regard to
calibration and cost-effectiveness. The Work Group members are uncertain whether more recent individual study results
have been published relevant to ABI. Updated systematic reviews addressing discrimination, calibration, reclassiﬁcation,
and cost issues in the context of the newer ASCVD risk assessment model proposed in this document are needed.
3 Emerging Risk
Factors
Collaboration (13)
hs-CRP “CRP concentration has continuous associations with the risk for coronary heart disease, ischaemic stroke, vascular
mortality, and death from several cancers and lung disease that are each of broadly similar size. The relevance of CRP
to such a range of disorders is unclear. Associations with ischaemic vascular disease depend considerably on
conventional risk factors and other markers of inﬂammation.”
hs-CRP is associated with risk of CVD. This analysis did not directly assess value in risk prediction. No additional
evidence was provided for discrimination, calibration, reclassiﬁcation, or cost-effectiveness.
4 Schnell-Inderst
et al., 2010 (17)
hs-CRP For MI and cardiovascular mortality, “Adding hs-CRP to traditional risk factors improves risk prediction, but the clinical
relevance and cost-effectiveness of this improvement remain unclear.”
Absolute differences in C-statistics between models including and not including hs-CRP ranged from 0.00 to 0.027.
Some evidence was provided to support the cost-effectiveness of hs-CRP testing in some modeling scenarios,
characterized by intermediate- and higher-risk populations and lower-cost (generic) statins of at least moderate efﬁcacy.
5 Emerging Risk
Factors
Collaboration (40)
ApoB This article provided evidence of rough equivalence of associations of CVD with non–HDL-C and ApoB after multivariable
adjustment (including HDL-C). See Figure 1 for CHD and the text for stroke. By inference, this ﬁnding means there would
be rough equivalence between ApoB and total cholesterol with similar adjustment.
6 Sniderman
et al., 2011 (42)
ApoB ApoB was more strongly related to risk of ASCVD than either non–HDL-C or LDL-C in a substitution model that also included
HDL-C. No evidence was presented pertinent to an addition model in which ApoB might be added to a model that
included total cholesterol, LDL-C, or non–HDL-C. Additional models are the type of model of interest to this question. By
inference, these results maymean that ApoB is more strongly related to risk than is total cholesterol. This article did not
address directly the value of adding ApoB to a model with traditional risk factors. No information was presented for
discrimination, calibration, reclassiﬁcation, or cost. The relative risks evaluated in the meta-analysis were adjusted for
various sets of covariates in the various primary reports, and the adjustments were judged to be incomplete.
Furthermore, studies of varying designs and quality were included, leaving the Work Group members concerned about
the validity of the evidence.
7 Kodama
et al., 2009 (41)
Cardiorespiratory
ﬁtness
Better cardiorespiratory ﬁtness was associated with lower risk of all-cause mortality and CHD/CVD. According to the
sensitivity analyses in Table 2, evidence of association was weaker for CHD/CVD, but still signiﬁcant, when based on
studies with more complete adjustment for other risk factors. The utility of assessing cardiorespiratory ﬁtness in risk
prediction was not assessed (discrimination, calibration, reclassiﬁcation, and cost).
Continued on the next page
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8 Ankle Brachial
Index
Collaboration (11)
ABI ABI is associated with total CHD risk and leads to signiﬁcant reclassiﬁcation, and the pattern of reclassiﬁcation is different
by sex. Among men, the effect is to down-classify high-risk men. Among women, the effect is to up-classify low-risk
women. Overall, the FRS, as applied by the investigators, showed relatively poor discrimination in this meta-analysis,
with C-statistics of 0.646 (95% CI: 0.643–0.657) in men and 0.605 (0.590–0.619) in women. There was an
improvement in C-statistic in both men (0.655 [0.643–0.666]) and women (0.658 [0.644–0.672]) when ABI was added
to a model with FRS. The improvement in the C-statistic was greater and signiﬁcant in women but was not signiﬁcant in
men. No evidence on calibration, net reclassiﬁcation index, or cost-effectiveness was provided.
9 Empana
et al., 2011 (10)
Family history
of CHD
“In separate models adjusted for age, gender, and study cohort, a family history of CHD, BMI, and waist circumference were
all predictors of CHD. When traditional risk factors were controlled for, family history of CHD (p<0.001) and BMI
(p¼0.03) but not waist circumference (p¼0.42) remained associated with CHD. However, the addition of family history
of CHD or BMI to the traditional risk factors model did not improve the discrimination of the model (not shown).”
This article developed a CHD risk prediction algorithm based on 4 French population studies and evaluated, among
other factors, the contribution of family history to traditional risk factors. Family history of CHD was deﬁned as the self-
report of a MI in ﬁrst-degree relatives (parents and siblings) in the D.E.S.I.R. and SU.VI.MAX studies, as a history of MI
before age 55 years in men and before age 65 years in women in parents, siblings, and grandparents in the PRIME
study, and as a death due to MI in ﬁrst-degree relatives in the Three City study. No evidence on calibration, net
reclassiﬁcation index, or cost-effectiveness was provided.
10 Moyer
et al., 2013 (15)
ABI This article is an updated review of the utility of assessing ABI for the USPSTF.
“The USPSTF concludes that the current evidence is insufﬁcient to assess the balance of beneﬁts and harms of
screening for PAD and CVD risk assessment with the ABI in adults. (I statement)”
“The USPSTF found no evidence that screening for and treatment of PAD in asymptomatic patients leads to clinically
important beneﬁts. It also reviewed the potential beneﬁts of adding the ABI to the FRS and found evidence that this
results in some patient risk reclassiﬁcation; however, how often the reclassiﬁcation is appropriate or whether it results in
improved clinical outcomes is not known.”
The Work Group notes that this review provides some evidence that assessing ABI may improve risk assessment;
however, no evidence was found by the USPSTF reviewers pertinent to the question of whether measuring ABI leads
to better patient outcomes.
11. Peters
et al., 2012 (16)
CIMT, CAC This article is a systematic review of the literature on the contribution to risk assessment of imaging for subclinical
atherosclerosis.
“Published evidence on the added value of atherosclerosis imaging varies across the different markers, with limited
evidence for FMD and considerable evidence for CIMT, carotid plaque and CAC. The added predictive value of additional
screening may be primarily found in asymptomatic individuals at intermediate cardiovascular risk. Additional research
in asymptomatic individuals is needed to quantify the cost-effectiveness and impact of imaging for subclinical
atherosclerosis on cardiovascular risk factor management and patient outcomes.”
With regard to CIMT:
“The c-statistic of the prediction models without CIMT increased from 0.00 to 0.03 when CIMT was added. In the
Atherosclerosis Risk In Communities (ARIC) study, addition of CIMT to the prediction model resulted in an NRI overall of
7.1% (95% CI 2.2% to 10.6%) and an IDI of 0.007 (95% CI 0.004 to 0.010). The NRI intermediate was 16.7% (95% CI
9.3% to 22.4%). In contrast, 10 year results from the Carotid Atherosclerosis Progression Study showed that addition of
CIMT to the prediction model resulted in an IDI of 0.04% and NRI overall of –1.41%. Analysis of 1,574 participants from
the Fireﬁghters and Their Endothelium study showed an NRI overall of 11.6% (p¼0.044) and an NRI intermediate of
18.0% (p¼0.034).”
The Work Group notes that this article provides some evidence to consider assessing CIMT; however, this conclusion was
not supported by the article by Den Ruijter et al. described below (18).
With regard to CAC:
“The c-statistic increased from 0.04 to 0.13 when CAC was added to the model. Four recently published studies also
reported results on the NRI and/or the IDI. One of these studies comprised a subgroup analysis of an earlier publication in
the total population in individuals without indications for statin therapy. Analyses of the MESA study showed that addition
of CAC to the conventional prediction model resulted in an NRI overall of 25% (95% CI 16% to 34%) and an NRI
intermediate of 55% (95% CI 41% to 69%). The IDI in the MESA study was 0.026. Results were similar in the Rotterdam
study. Addition of CAC to the prediction model led to an NRI overall of 14% (p<0.01) which was mainly driven by correctly
reclassifying those at intermediate risk according to the traditional prediction model. Results from the Heinz Nixdorf
Recall study also showed large NRIs when CAC was added to the Framingham Risk Score. Using different thresholds to
deﬁne the intermediate risk category (10%–20% or 6%–20%), the NRI overall was 22% and 20%, respectively. The NRI
intermediate was 22% for intermediate risk thresholds of 10%–20% and 31% for intermediate risk thresholds of
6%–20%. In addition, the IDI was 0.0152 when the prediction models with and without CAC were compared. The NRI
overall was 25.1% and the IDI was 0.0167 in individuals from the Heinz Nixdorf Recall study without indications for statin
therapy.” The Work Group notes that this article provides evidence to support the conclusion that assessing CAC is likely
to be the most useful approach to improving risk assessment among individuals found to be at intermediate risk after
formal risk assessment. Furthermore, we note that the outcomes in the studies reviewed above were CHD, not ASCVD.
The Work Group discussed concerns about cost, radiation exposure, and the uncertainty of the contribution of assessing
CAC to estimation of 10-year risk of hard ASCVD after formal risk assessment.
12. Kashani
et al., 2013 (14)
Family
history
This article is an integrative literature review on the contribution of assessing family history to risk appraisal.
“The evidence demonstrates that family history is an independent contributor to risk appraisal and unequivocally
supports its incorporation to improve accuracy in global CVD risk estimation.”
The Work Group notes that a variety of endpoints, clinical and subclinical, were included in the reviewed articles.
No evidence on discrimination, calibration, net reclassiﬁcation index, or cost-effectiveness was provided.
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13. Den Ruijter
et al., 2012 (18)
CIMT This article is an individual-level meta-analysis of “14 population-based cohorts contributing data for 45 828 individuals.
During a median follow-up of 11 years, 4007 ﬁrst-time MIs or strokes occurred.”
“We ﬁrst reﬁtted the risk factors of the FRS and then extended the model with common CIMT measurements to
estimate the absolute 10-year risks to develop a ﬁrst-time MI or stroke in both models. The C-statistic of both models
was similar (0.757; 95% CI, 0.749–0.764; and 0.759; 95% CI, 0.752–0.766). The net reclassiﬁcation improvement with
the addition of common CIMT was small (0.8%; 95% CI, 0.1%–1.6%). In those at intermediate risk, the net
reclassiﬁcation improvement was 3.6% in all individuals (95% CI, 2.7%–4.6%) and no differences between men and
women.”
“The addition of common CIMT measurements to the FRS was associated with small improvement in 10-year risk
prediction of ﬁrst-time MI or stroke, but this improvement is unlikely to be of clinical importance.”
The Work Group judged this article to provide the strongest evidence available on the potential value of CIMT to risk
assessment. The Work Group also has concerns about measurement issues. Standardization of CIMT measurement is a
major challenge.
ABI indicates ankle-brachial index; ApoB, apolipoprotein B; BMI, body mass index; ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcium; CHD, coronary heart disease; CI,
conﬁdence interval; CIMT, carotid intima-media thickness; CRP, C-reactive protein; CVD, cardiovascular disease; FMD, ﬂow-mediated dilation; FRS, Framingham Risk Score; HDL-C, high-density lipo-
protein cholesterol; hs-CRP, high-sensitivity C-reactive protein; IDI, integrative discrimination index; JUPITER, Justiﬁcation for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating
Rosuvastatin; LDL-C, low-density lipoprotein cholesterol; MESA, Multi-Ethnic Study of Atherosclerosis; NRI, net reclassiﬁcation index; PAD, peripheral artery disease; MI, myocardial infarction; and
USPSTF, U.S. Preventive Services Task Force.
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Statement
Number Evidence Stateme
1. We found no evidence assessing variations in long-term or lifetime risk
intermediate short-term risk in racial/ethnic groups other than non-H
Strength of Evidence: None
2. ASCVD risk factors measured in young and middle-aged adults, conside
short-term (10 years), long-term (15 years), and lifetime risk of A
Strength of Evidence: Low (for diabetes and metabolic syndrome) to M
3. Multivariable short-term (10-year) CHD risk prediction models underestim
lifetime risk of CHD in women and older men.*
Strength of Evidence: Low
*CHD is deﬁned as all manifestations of CHD, or as CHD death/nonf
4. Long-term (30-year) risk equations based on traditional ASCVD risk fact
ASCVDy risk than do extrapolations of short-term (10-year) risk equat
free from ASCVD.
Strength of Evidence: Low
*Age, sex, total cholesterol, HDL-C, systolic BP, use of antihypertensiv
yCHD death, nonfatal MI, or fatal/nonfatal stroke; or all ASCVD.
5. The presence and severity of selected traditional ASCVD risk factors* st
non-Hispanic white adults 45–50 years of age who are free of ASCVD
Strength of Evidence: Low
*Risk factors were considered in 5 mutually exclusive strata encomp
1) 2 major risk factors (deﬁned as total cholesterol 240 mg/dL or
or treated, or diabetes, or current smoking) and lifetime risk of ASCV
ASCVD 39%–50%; 3) 1 elevated risk factor (deﬁned as untreated to
BP 140–159 mm Hg or diastolic BP 90–99 mm Hg, and no diabetes
39%–46%; 4) 1 risk factor at nonoptimal levels (untreated total cho
120–139 mm Hg or diastolic BP 80–89 mm Hg, and no diabetes an
27%–36%; and 5) all optimal levels of risk factors (deﬁned as untrea
BP <120/<80 mm Hg, and no diabetes, and no current smoking) an
yCHD death, MI, coronary insufﬁciency, angina, fatal/nonfatal atherot
6. Long-term (15 years) risk prediction models based on selected traditio
good discrimination and calibration, and better in women than men,
Strength of Evidence: Low
*Age, sex, total cholesterol, systolic BP, diabetes, and smoking.
7. Measuring and updating ASCVD risk factors every 4–6 years improves s
Strength of Evidence: Moderate
ASCVD indicates atherosclerotic cardiovascular disease; BMI, body mass index; BP, blood pressure; CHD
lipoprotein cholesterol; MI, myocardial infarction; and d, none.nt References
of CVD outcomes among persons at low or
ispanic whites in the United States and Europe.
d
red singly or jointly, generally are associated with
SCVD.
oderate (for BMI, cholesterol, systolic BP, and smoking).
(20,21,47,48,51,52)
ate absolute lifetime risk of CHD but maystratify relative
atal MI.
(22)
ors* provide more accurate prediction of long-term
ions among individuals 20–59 years of age who are
e therapy, diabetes, and current smoking.
(20)
ratify absolute levels of lifetime risk of ASCVDy among
and not at high short-term risk.
assing the full spectrum of risk levels, as follows:
treated, systolic BP 160 or diastolic BP 100 mm Hg
D >50%; 2) only 1 major risk factor and lifetime risk of
tal cholesterol 200 to 239 mg/dL, or untreated systolic
and no current smoking) and lifetime risk of ASCVD
lesterol 180–199 mg/dL, or untreated systolic BP
d no current smoking) and lifetime risk of ASCVD
ted total cholesterol <180 mg/dL, and untreated
d lifetime risk of ASCVD <10%.
hrombotic stroke, claudication, other CVD death.
(21)
nal ASCVD risk factors* predict CHD death with
in U.S. non-Hispanic white populations.
(50)
hort- and long-term risk prediction. (19,20)
, coronary heart disease; CQ, critical question; CVD, cardiovascular disease; HDL-C, high-density
Appendix 6. Characteristics of Previously Published Risk Scores and Current Pooled Cohort Equations
(Including Data Sources, Covariates, and Outcomes)
CVD Events
Hard CVD, Including Cardiac Failure
Hard ASCVD
Hard CHD
Total CHD
Risk Score Risk Factors/Covariates Included Total CHD, Including Revascularization
Study
Group
Study and
Region
Data
Source
Publication
Year Age Sex
Total
Chol
LDL
Chol
HDL
Chol CRP
Systolic
BP
BP
Rx Diabetes HbA1c* Smoking
Family
Hx
CVDy
Body
Mass
Index Social Region
Coronary
Revasc
Angina
Pectoris
Unstable
Angina
Myocardial
Infarct
CHD
Death Stroke
Stroke
Death
Cardiac
Failure TIA
Framingham
CHD (57)
Framingham
MA, USA
EAF, EAM 1998 x x x x x x x x x x x x
ATP III (24) Framingham
MA, USA
EAF, EAM 2001 x x x x x x x x x
Framingham
Global (58)
Framingham
MA, USA
EAF, EAM 2008 x x x x x x x x x x x x x
PRO-CAM (59) Muenster,
Germany
EM 2002 x x x x x x x x x
QRISK (60) QRESEARCH,
United
Kingdom
EF, EM 2007 x x x x x x x x x xz x x x x x x x x x
Reynolds
Men (61)
Phys Health
Study
USA
EAF 2008 x x x x x x x x x x x x
Reynolds
Women (62)
Women’s
Health Study
USA
EAM 2007 x x x x x x x x x x x x x
EURO-SCORE
(63)
12 cohorts
Europe
EF, EM 2003 x x x x x x x x x
Pooled Cohort
(current)
CARDIA,
Framingham,
ARIC, CHS,USA
EAF, EAM
AAF,
AAM
x x x x x x x x x x x x
*Only among those with diabetes.
yDeﬁnitions of a positive family history vary.
zMeasure of social deprivation.
AAF indicates African-American females; AAM, African-American males; ARIC, Atherosclerosis Risk in Communities study; ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; CARDIA, Coronary Artery Risk Development in Young Adults study; CHD, coronary
heart disease; Chol, cholesterol; CHS, Cardiovascular Health Study; CRP, C-reactive protein; CVD, cardiovascular disease; EAF, European-American females; EAM, European-American males; EF, European females; EM, European males; EURO-SCORE, European System for
Cardiac Operative Risk Evaluation; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; Hx, history; LDL, low-density lipoprotein; Revasc, revascularization; Rx, medication; and TIA, transient ischemic attack.
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2957Appendix 7. Development and Steps
for Implementation of the ASCVD
Pooled Cohort Risk Equations
Prior experience with the development of the Framingham
Heart Study 10-year CHD risk prediction equations
(24,57) and the more recent Framingham 10-year general
CVD risk prediction equations (58), was used as a basis for
developing the new Pooled Cohort Risk Equations. To
expand the utility and generalizability of the new equa-
tions, extensive data were used from several large, racially
and geographically diverse, modern NHLBI-sponsored
cohort studies, including the ARIC (Atherosclerosis Risk
in Communities) study (8), Cardiovascular Health Study
(5), and the CARDIA (Coronary Artery Risk Develop-
ment in Young Adults) study (7), combined with appli-
cable data from the Framingham Original and Offspring
Study cohorts (4,6).
A total of 11,240 white women (who experienced 902
hard ASCVD events), 9,098 white men (1,259 hard
ASCVD events), 2,641 African-American women (290
hard ASCVD events), and 1,647 African-American men
(238 hard ASCVD events) who met the following criteria
were included: 40 to 79 years of age, apparently healthy,
and free of a previous history of nonfatal myocardial
infarction (recognized or unrecognized), stroke, heart
failure, percutaneous coronary intervention, coronary artery
bypass surgery, or atrial ﬁbrillation. Data from the included
participants were used to develop sex- and race-speciﬁc
equations to predict 10-year risk of a ﬁrst hard ASCVD
event. Because of the growing health burden of heart
failure, the Work Group examined the possibility of
including heart failure as an outcome. However, study-by-
study ascertainment and adjudication of heart failure varied
considerably, and therefore heart failure could not be
included as an outcome. Because of known substantial
geographic variation in use (Dartmouth Atlas of Health-
care, http://www.dartmouthatlas.org/), self-selection, and
physician recommendation biases (64), coronary revascu-
larization was also not included as an endpoint.
The Pooled Cohort Equations for estimating ASCVD
were developed from sex- and race-speciﬁc proportional-
hazards models that included the covariates of age, treated
or untreated systolic BP level, total cholesterol and high-
density lipoprotein cholesterol levels, current smoking sta-
tus (yes/no), and history of diabetes (yes/no). A variable
representing lipid treatment was considered but not
retained in the ﬁnal model because lipid therapy was rela-
tively uncommon in the cohorts and statistical signiﬁcance
was lacking. Baseline characteristics of the participantsincluded in the equation derivation model are shown in the
Full Work Group Report Data supplement, as are details of
the methods used to derive, evaluate, and validate (inter-
nally and externally) the resulting risk equations and their
potential limitations. In summary, discrimination and
calibration of the models were very good. C-statistics
ranged from a low of 0.713 (African-American men) to a
high of 0.818 (African-American women). Calibration chi-
square statistics ranged from a low of 4.86 (non-Hispanic
white men) to a high of 7.25 (African-American women).
The coefﬁcients for the equations for calculating an esti-
mate of an individual’s 10-year risk of a ﬁrst hard ASCVD
event are provided in Table A, along with examples based
on a speciﬁc risk proﬁle for each race–sex group. The step-
by-step process for estimating the risk in the speciﬁc ex-
amples of Table A is provided in Table B. These 2 tables
are intended to enable programmers to integrate these
equations into electronic health records.
The Work Group also considered the inclusion of
additional and novel risk markers in the risk equations. On
the basis of the availability of data across cohorts at
applicable examination cycles, additional risk markers were
evaluated for potential inclusion if they improved model
performance within the framework of Hlatky et al (39).
The additional risk markers that were evaluated included
diastolic BP, family history of ASCVD, moderate or severe
chronic kidney disease (deﬁned as an estimated glomerular
ﬁltration rate of <60 mL/min per 1.73 m2 ) (65), and body
mass index (continuous or categorical). None of these
variables signiﬁcantly improved discrimination for 10-year
hard ASCVD risk prediction when added to the ﬁnal base
models. Other risk markers (hs-CRP, ApoB, micro-
albuminuria, cardiorespiratory ﬁtness, CAC score, CIMT,
and ABI) could not be evaluated in creating this new
model because of absence of data or lack of inclusion in
the appropriate examination cycle of 1 or more of the
studies. Therefore, these and the other risk markers were
addressed in CQ1 as potential adjuncts to quantitative risk
estimation.
Further research using state-of-the art statistical tech-
niques (including net reclassiﬁcation improvement and
integrative discrimination index [66]) is needed to examine
the utility of novel biomarkers when added to these new
Pooled Cohort Equations in different populations and
patient subgroups. Randomized clinical trials demon-
strating the utility of screening with novel risk markers
would represent the best evidence for their inclusion in
future risk assessment algorithms. In the absence of evi-
dence from trials, methodologically rigorous observational
studies should be conducted to evaluate utility.
Table A. Equation Parameters of the Pooled Cohort Equations for Estimation of 10-Year Risk of Hard ASCVD*
and Speciﬁc Examples for Each Race and Sex Group
White African American
Coefﬁcient
Individual Example
Value
Coefﬁcient
 Valuey Coefﬁcient
Individual Example
Value
Coefﬁcient
 Valuey
Women (Example: 55 years of age with total cholesterol 213 mg/dL, HDL-C 50 mg/dL, untreated systolic BP 120 mm Hg, nonsmoker, and without diabetes)
Ln Age (y) –29.799 4.01 –119.41 17.114 4.01 68.58
Ln Age, Squared 4.884 16.06 78.44 N/A N/A N/A
Ln Total Cholesterol (mg/dL) 13.540 5.36 72.59 0.940 5.36 5.04
Ln Age  Ln Total Cholesterol –3.114 21.48 –66.91 N/A N/A N/A
Ln HDL-C (mg/dL) –13.578 3.91 –53.12 –18.920 3.91 –74.01
Ln Age  Ln HDL-C 3.149 15.68 49.37 4.475 15.68 70.15
Ln Treated Systolic BP (mm Hg) 2.019 d d 29.291 d d
Ln Age  Ln Treated Systolic BP N/A N/A N/A –6.432 d d
Ln Untreated Systolic BP (mm Hg) 1.957 4.79 9.37 27.820 4.79 133.19
Ln Age  Ln Untreated Systolic BP N/A N/A N/A –6.087 19.19 –116.79
Current Smoker (1¼Yes, 0¼No) 7.574 0 0 0.691 0 0
Ln Age  Current Smoker –1.665 0 0 N/A N/A N/A
Diabetes (1¼Yes, 0¼No) 0.661 0 0 0.874 0 0
Individual Sum –29.67 86.16
Mean (Coefﬁcient  Value) N/A N/A –29.18 N/A N/A 86.61
Baseline Survival N/A N/A 0.9665 N/A N/A 0.9533
Estimated 10-y Risk of Hard ASCVD N/A N/A 2.1% N/A N/A 3.0%
Men (Example: 55 years of age with total cholesterol 213 mg/dL, HDL-C 50 mg/dL, untreated systolic BP 120 mm Hg, nonsmoker, and without diabetes)
Ln Age (y) 12.344 4.01 49.47 2.469 4.01 9.89
Ln Total Cholesterol (mg/dL) 11.853 5.36 63.55 0.302 5.36 1.62
Ln Age  Ln Total Cholesterol –2.664 21.48 –57.24 N/A N/A N/A
Ln HDL-C (mg/dL) –7.990 3.91 –31.26 –0.307 3.91 –1.20
Ln Age  Ln HDL-C 1.769 15.68 27.73 N/A N/A N/A
Ln Treated Systolic BP (mm Hg) 1.797 d d 1.916 d d
Ln Untreated Systolic BP (mm Hg) 1.764 4.79 8.45 1.809 4.79 8.66
Current Smoker (1¼Yes, 0¼No) 7.837 0 0 0.549 0 0
Ln Age  Current Smoker –1.795 0 0 N/A N/A N/A
Diabetes (1¼Yes, 0¼No) 0.658 0 0 0.645 0 0
Individual Sum 60.69 18.97
Mean (Coefﬁcient  Value) N/A N/A 61.18 N/A N/A 19.54
Baseline Survival N/A N/A 0.9144 N/A N/A 0.8954
Estimated 10-y Risk of Hard ASCVD N/A N/A 5.3% N/A N/A 6.1%
*Deﬁned as ﬁrst occurrence of nonfatal myocardial infarction or CHD death, or fatal or nonfatal stroke.
yCoefﬁcient  Value: For age, lipids, and BP, deﬁned as the natural log of the value multiplied by the parameter estimate. When an age interaction is present with lipids or BP, the natural log of age is
multiplied by the natural log of the lipid or BP, and the result is multiplied by the parameter estimate. N/A indicates that that speciﬁc covariate was not included in the model for that sex–race group;d
indicates that this value was not included in the example (e.g., this example used untreated systolic BP, not treated systolic BP).
ASCVD indicates atherosclerotic cardiovascular disease; BP indicates blood pressure; CHD, coronary heart disease; HDL-C, high-density lipoprotein cholesterol; Ln, natural logarithm; and N/A, not
included.
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Table B. Estimating an Individual’s 10-Year Risk of Incident Hard ASCVD
The hypothetical proﬁle provided in Table 5 (the “Individual Example Value” column) is identical for each race and sex group and is based on the overall sample mean.
The proﬁle assumes an individual 55 years of age (for which the Ln[Age]¼4.01), with a total cholesterol of 213 mg/dL, HDL-C of 50 mg/dL, and an untreated
systolic BP of 120 mm Hg. This individual is not a current smoker and does not have diabetes. For the equations, the values for age, lipids, and systolic BP are Ln
transformed. Interactions between age and lipids or age and systolic BP use the natural log of each variable (e.g., Ln[Age]Ln[Total Cholesterol]).
Calculation of the 10-year risk estimate for hard ASCVD can best be described as a series of steps. The natural log of age, total cholesterol, HDL-C, and systolic BP are
ﬁrst calculated with systolic BP being either a treated or untreated value. Any appropriate interaction terms are then calculated. These values are then multiplied by
the coefﬁcients from the equation (“Coefﬁcient” column of Table A) for the speciﬁc race-sex group of the individual. The “Coefﬁcient  Value” column in the table
provides the results of the multiplication for the risk proﬁle described above.
The sum of the “Coefﬁcient  Value” column is then calculated for the individual. For the proﬁle shown in Table A, this value is shown as “Individual Sum” for each race
and sex group.
The estimated 10-year risk of a ﬁrst hard ASCVD event is formally calculated as 1 minus the survival rate at 10 years (“Baseline Survival” in Table A), raised to the
power of the exponent of the “Coefﬁcient  Value” sum minus the race- and sex-speciﬁc overall mean “Coefﬁcient  Value” sum; or, in equation form:
1 SeðlndX’BMeanX’BÞ10
Using white men as an example:
1 0:9144eð60:6961:18Þ
equates to a 5.3% probability of a ﬁrst hard ASCVD event within 10 years.
ASCVD indicates atherosclerotic cardiovascular disease; BP, blood pressure; HDL-C, high-density lipoprotein cholesterol; and Ln, natural logarithm.
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